Remdesivir
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic and Lymphatic System Neoplasm
Conditions
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
Trial Timeline
Dec 23, 2025 → Nov 30, 2027
NCT ID
NCT06817889About Remdesivir
Remdesivir is a phase 2 stage product being developed by Gilead Sciences for Hematopoietic and Lymphatic System Neoplasm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06817889. Target conditions include Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04323761 | Pre-clinical | Completed |
| NCT06817889 | Phase 2 | Recruiting |
| NCT04582266 | Pre-clinical | Completed |
| NCT04847622 | Pre-clinical | Completed |
| NCT04431453 | Phase 2/3 | Completed |
Competing Products
20 competing products in Hematopoietic and Lymphatic System Neoplasm